ConvaTec Group (LON:CTEC) PT Lowered to GBX 290 at JPMorgan Chase & Co.

ConvaTec Group (LON:CTEC) had its price target lowered by JPMorgan Chase & Co. from GBX 323 ($4.15) to GBX 290 ($3.73) in a report published on Wednesday morning, MarketBeat.com reports. The brokerage currently has an overweight rating on the stock.

Separately, Berenberg Bank reiterated a buy rating and set a GBX 310 ($3.99) price objective on shares of ConvaTec Group in a report on Tuesday, June 11th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has a consensus rating of Buy and a consensus target price of GBX 302.50 ($3.89).

ConvaTec Group Stock Performance

ConvaTec Group stock opened at GBX 232 ($2.98) on Wednesday. The stock has a fifty day moving average price of GBX 244.87 and a 200 day moving average price of GBX 256.38. ConvaTec Group has a 52 week low of GBX 195.10 ($2.51) and a 52 week high of GBX 295.20 ($3.80). The firm has a market capitalization of £4.76 billion, a P/E ratio of 4,640.00, a PEG ratio of 2.10 and a beta of 0.60. The company has a current ratio of 1.62, a quick ratio of 0.96 and a debt-to-equity ratio of 77.53.

ConvaTec Group Cuts Dividend

The firm also recently disclosed a dividend, which will be paid on Friday, October 4th. Shareholders of record on Thursday, August 22nd will be paid a dividend of $0.02 per share. The ex-dividend date is Thursday, August 22nd. This represents a yield of 0.56%. ConvaTec Group’s dividend payout ratio is currently 10,000.00%.

ConvaTec Group Company Profile

ConvaTec Group PLC engages in the development, manufacturing, and sale of medical products, services, and technologies in Europe, North America, and internationally. The company offers advanced wound dressings and skin care products for the management of acute and chronic wounds resulting from various conditions, such as diabetes, and acute conditions resulting from traumatic injury and burns.